Uprima Selective ED Population Should Be Reflected In Labeling, Cmte. Says
Executive Summary
TAP's Uprima labeling should describe the selective population of men with erectile dysfunction who were enrolled in clinical trials of the drug, FDA's Reproductive Health Drugs Committee Urologics Subcommittee said April 10.
You may also be interested in...
TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says
TAP will refile an NDA for the erectile dysfunction disorder drugUprima in the fourth quarter, Abbott Pharmaceuticals President Jeff Leiden, MD/PhD, told analysts on a first quarter conference call April 9
TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says
TAP will refile an NDA for the erectile dysfunction disorder drugUprima in the fourth quarter, Abbott Pharmaceuticals President Jeff Leiden, MD/PhD, told analysts on a first quarter conference call April 9
TAP Uprima 3 Mg Dose Studies To Be Completed This Summer; NDA Withdrawn
TAP expects to complete additional Uprima efficacy and safety studies using a 3 mg dose this summer.